L-2-hydroxyglutaric acid inhibits mitochondrial creatine kinase activity from cerebellum of developing rats.
L-2-Hydroxyglutaric acid (LGA) is the biochemical hallmark of patients affected by the neurometabolic disorder known as L-2-hydroxyglutaric aciduria (LHGA). Although this disorder is predominantly characterized by severe neurological findings and pronounced cerebellum atrophy, the neurotoxic mechanisms of brain injury are virtually unknown. In the present study, we investigated the effect of LGA, at 0.25-5mM concentrations, on total creatine kinase (tCK) activity from cerebellum, cerebral cortex, cardiac muscle and skeletal muscle homogenates of 30-day-old Wistar rats. CK activity was measured also in the cytosolic (Cy-CK) and mitochondrial (Mi-CK) fractions from cerebellum. We verified that tCK activity was significantly inhibited by LGA in the cerebellum, but not in cerebral cortex, cardiac muscle and skeletal muscle. Furthermore, CK activity from the mitochondrial fraction was inhibited by LGA, whereas that from the cytosolic fraction of cerebellum was not affected by the acid. Kinetic studies revealed that the inhibitory effect of LGA on Mi-CK was non-competitive in relation to phosphocreatine. Finally, we verified that the inhibitory effect of LGA on tCK was fully prevented by pre-incubation of the homogenates with reduced glutathione (GSH), suggesting that this inhibition is possibly mediated by oxidation of essential thiol groups of the enzyme. Considering the importance of creatine kinase activity for energy homeostasis, our results suggest that the selective inhibition of this enzyme activity by increased levels of LGA could be possibly related to the cerebellar degeneration characteristically found in patients affected by L-2-hydroxyglutaric aciduria.
da Silva
Cleide G
CG
Department of Biochemistry, Institute of Basic Sciences and Health, UFRGS, Av. Ramiro Barcellos 2600, Porto Alegre, RS, Brazil.
Bueno
Ana Rúbia F
AR
Schuck
Patrícia F
PF
Leipnitz
Guilhian
G
Ribeiro
César A J
CA
Wannmacher
Clóvis M D
CM
Wyse
Angela T S
AT
Wajner
Moacir
M
D000818:Animals; D001205:Ascorbic Acid / Q000494:pharmacology; D020739:Brain Diseases, Metabolic, Inborn / Q000378:metabolism; D002531:Cerebellum / Q000187:drug effects / Q000196:embryology* / Q000201:enzymology*; D002540:Cerebral Cortex / Q000187:drug effects / Q000196:embryology / Q000201:enzymology; D003402:Creatine Kinase / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D052281:Creatine Kinase, Mitochondrial Form; D005977:Glutarates / Q000494:pharmacology*; D005978:Glutathione / Q000494:pharmacology; D006321:Heart / Q000187:drug effects / Q000196:embryology; D007527:Isoenzymes / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D008928:Mitochondria / Q000187:drug effects / Q000201:enzymology; D018482:Muscle, Skeletal / Q000187:drug effects / Q000196:embryology / Q000201:enzymology; D009206:Myocardium / Q000201:enzymology; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009928:Organ Specificity; D051381:Rats; D017208:Rats, Wistar; D024502:alpha-Tocopherol / Q000494:pharmacology
D005977:Glutarates; D007527:Isoenzymes; C019417:alpha-hydroxyglutarate; D003402:Creatine Kinase; D052281:Creatine Kinase, Mitochondrial Form; D005978:Glutathione; D024502:alpha-Tocopherol; D001205:Ascorbic Acid; D019331:NG-Nitroarginine Methyl Ester